Another UK Biotech Snapped Up As Neurocrine Buys Diurnal informa.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from informa.com Daily Mail and Mail on Sunday newspapers.
Neurocrine Biosciences is acquiring Diurnal Group, a U.K-based biotech that has commercialized two endocrine disorder drugs. Neurocrine’s top-selling product is a blockbuster drug for an involuntary muscle movement disorder.
Neurocrine Biosciences, Inc. (NASDAQ:NASDAQ:NBIX) Q1 2022 Earnings Conference Call May 04, 2022, 08:00 ET Company Participants Todd Tushla - VP, IR Kevin Gorman - CEO & Director Matthew.